LivaNova PLC (NASDAQ:LIVN) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on LivaNova, with six buy ratings and five holds. The average 12-month price target is $84.13, with recent targets ranging as high as $95.
• LivaNova reported quarterly results above expectations, posting EPS of $1.26 versus the $1.09 consensus and revenue of $390.59 million. Revenue increased 10.8% year over year.
• The stock opened at $78.18, compared with a 52-week range of $48.82 to $85.76, while institutional investors own 97.64% of outstanding shares; two directors recently sold shares.

Shares of LivaNova PLC (NASDAQ:LIVN - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $84.1250.

LIVN has been the topic of a number of analyst reports. Mizuho lifted their price objective on shares of LivaNova from $90.00 to $95.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Piper Sandler restated an "overweight" rating and set a $90.00 price objective (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. Stifel Nicolaus set a $85.00 target price on shares of LivaNova in a report on Wednesday, August 5th. Freedom Capital raised shares of LivaNova to a "hold" rating in a report on Tuesday, June 30th. Finally, Zacks Research lowered shares of LivaNova from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th.

Insider Buying and Selling

In other LivaNova news, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director owned 7,488 shares of the company's stock, valued at approximately $609,672.96. The trade was a 23.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Francesco Bianchi sold 1,650 shares of the business's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $79.72, for a total value of $131,538.00. Following the transaction, the director owned 7,934 shares in the company, valued at $632,498.48. The trade was a 17.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Allworth Financial LP raised its position in LivaNova by 93.5% in the second quarter. Allworth Financial LP now owns 298 shares of the company's stock worth $25,000 after acquiring an additional 144 shares in the last quarter. Hantz Financial Services Inc. boosted its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company's stock worth $27,000 after purchasing an additional 267 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of LivaNova during the 2nd quarter worth $37,000. State of Wyoming acquired a new position in shares of LivaNova during the 2nd quarter worth $31,000. Finally, Quarry LP purchased a new position in shares of LivaNova in the 3rd quarter valued at about $36,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Stock Performance

Shares of LIVN stock opened at $78.18 on Monday. The stock's 50-day moving average price is $80.35 and its 200 day moving average price is $73.36. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $4.31 billion, a PE ratio of 23.13 and a beta of 0.87. LivaNova has a 52-week low of $48.82 and a 52-week high of $85.76.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The company had revenue of $390.59 million during the quarter, compared to analysts' expectations of $380.50 million. During the same period last year, the firm earned $1.05 EPS. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. As a group, equities research analysts forecast that LivaNova will post 3.77 EPS for the current year.

LivaNova Company Profile

LivaNova PLC NASDAQ: LIVN is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova's Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.